New injection aims to tame chronic hepatitis b
NCT ID NCT07673068
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This early-stage trial tests an injection called TVAX-028 in adults with chronic hepatitis B. The study checks if the drug is safe and how the body processes it. Participants receive either TVAX-028 with an adjuvant or the adjuvant alone, at different dose levels. The goal is to gather initial safety data before larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TVAX-028 injection (with adjuvant)
What this could lead to
If safe and effective, this could lead to a new treatment option for chronic hepatitis B, potentially helping control the virus long-term.
What could go wrong
This is an early Phase 1 trial with only 32 participants, focused on safety. It is too soon to know if TVAX-028 will work, and side effects are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HBV INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••